The Trump administration said it was transferred to end the extensive funds for HIV vaccine research, and the current approach is enough to respond to the virus.
This story continued CBS News.
You cannot post again.
Notifications that the funds will not be extended were delivered to researchers who were delivered on May 30. National Institute of Health That civil servant Ministry of Health and Welfare Instead, they have been elected to “take the current approach to remove the current HIV.”
Reduction will close two major HIV vaccine research efforts that NIH first funded. 2012 Scientists said in the Duke Human Vaccine Institute and Scripps Research Institute. Moderna spokesman said the vaccine manufacturer said Clinical trial NIH’s HIV vaccine test has also been suspended.
An NIH official said that HHS ordered not to issue funds anymore with a small number of exceptions to not issue funds for the research of HIV vaccines in the next fiscal year.
The change of budget rules for HIV vaccine research is also expected to reduce the NIH image of the research that scientists started.
This change will soon increase the accounting for previous research costs to HIV vaccines that support funds. NIH said that the company plans to calculate the HIV vaccine dollars only once a year from the multi -year subsidies instead of five years of subsidies, and officials said it was more difficult to raise funds.
HHS spokesman told CBS News that “complex and complex health programs have seriously overlapped serious efforts,” and “27 separate programs dealing with HIV/AIDS.”
“The administration believes that the United States should have the world’s best medical research. To this end, the administration is developing a policy to maximize the influence of all federal taxpayers and guarantee the appropriate supervision of this fund.”
Hilliard argued that the Critical Hiv/AIDS program will continue, under the new organization that Robert F. Kennedy Jr. was called the administration of Healthy American.
“In the case of HIV vaccine design and development, we have begun to see the light at the end of the tunnel after many years of research. This is a terrible time for breaking. We started getting closer. We are getting good results in clinical trials.” Dennis buttonProfessor of immunology at Scripps Research.
Burton warned that even if the future administration decided to change the HIV funding process, his institution’s research on HIV vaccines could not be turned on simply. He said that ongoing experiments will be closed and that researchers should focus their career on other topics collected to study this problem.
“This is a decision that remains, which is probably 10 years of frustration for the study of HIV vaccines.
The cancellation of funds comes several weeks before the FDA. June 19 deadline Drugs that can be injured every two years to prevent HIV to determine the approval of Lenacapavir.
The drug that pharmaceutical company Gilead Sciences is brought to the commercial market NIH support study As an early HIV drug. The availability of this drug can significantly reduce HIV cases worldwide. Research has been found It was 100% effective to prevent transmission.
NIH officials who do not have the authority to speak publicly rebuked the claim that the effect of HIV prevention strategy is no longer necessary. “The only way to end HIV epidemic in the United States is the worldwide epidemic and AIDS PANDEMIC,” the official said.
Developing effective HIV vaccines has become a difficult object for researchers, but scientists have recently welcomed groundbreaking innovation in the field.
“HIV has fought against us, we had to learn how to learn and overcome it,” said Barton Ford Haynes, a medical professor at Barton Ford Haynes, a part of Duke Human Vaccine Institute.
Haynes said his research is a combination of other vaccines as part of a strategy to design effective HIV vaccines.
He praised Lenacapavir for “great development in the field,” but he still needs a vaccine. Lenacapavir requires injections every six months, and it is also difficult to reduce the steep cuts to the Korea HIV program and US support HIV/AIDS foreign aid programs.
Haynes said, “We hoped to add an HIV vaccine to all our preventive measures to end the epidemic.
This article cannot be used for syndicate due to the restriction of re -publishing. If you have any questions about the availability of this content or other content, please contact news-web@kff.org.
